In this study, we aimed to analyze the TURKMI registry to identify the factors associated with delays from symptom onset to treatment that would be the focus of improvement efforts in patients with acute myocardial infarction (AMI) in Turkey. The TURKMI study is a nation-wide registry that was conducted in 50 centers capable of 24/7 primary percutaneous coronary intervention (PCI). All consecutive patients (n=1930) with AMI admitted to coronary care units within 48 hours of symptom onset were prospectively enrolled during a predefined 2-week period between November 1, 2018, and November 16, 2018. All the patients were examined in detail with regard to the time elapsed at each step from symptom onset to initiation of treatment, including door-to-balloon time (D2B) and total ischemic time (TIT). After excluding patients who suffered an AMI within the hospital (2.6%), the analysis was conducted for 1879 patients. Most of the patients (49.5%) arrived by self-transport, 11.8% by emergency medical service (EMS) ambulance, and 38.6% were transferred from another EMS without PCI capability. The median time delay from symptom-onset to EMS call was 52.5 (15-180) min and from EMS call to EMS arrival 15 (10-20) min. In ST-segment elevation myocardial infarction (STEMI), the median D2B time was 36.5 (25-63) min, and median TIT was 195 (115-330) min. TIT was significantly prolonged from 151 (90-285) min to 250 (165-372) min in patients transferred from non-PCI centers. The major significant factors associated with time delay were patient-related delay and the mode of hospital arrival, both in STEMI and non-STEMI. The baseline evaluation of the TURKMI study revealed that an important proportion of patients presenting with AMI within 48 hours of symptom onset reach the PCI treatment center later than the time proposed in the guidelines, and the use of EMS for admission to hospital is extremely low in Turkey. Patient-related factors and the mode of hospital admission were the major factors associated with the time delay to treatment.

Aim: We aimed to evaluate the awareness of pneumococcal vaccination (PCV13, PPSV23) in general cardiology outpatient clinics and impact of physicians’ recommendations on vaccination rates. Methods: This was a multicenter, observational, prospective cohort study. Patients over the age of 18 from 40 hospitals in different regions of Turkey who applied to the cardiology outpatient clinic between September 2022 and August 2021 participated. The vaccination rates were calculated within three months of follow-up from the admitting of the patient to cardiology clinics. Results: The 403 (18.2%) patients with previous pneumococcal vaccination were excluded from the study. The mean age of study population (n = 1808) was 61.9 ± 12.1 years and 55.4% were male. The 58.7% had coronary artery disease, hypertension (74.1%) was the most common risk factor, and 32.7% of the patients had never been vaccinated although they had information about vaccination before. The main differences between vaccinated and unvaccinated patients were related to education level and ejection fraction. The physicians’ recommendations were positively correlated with vaccination intention and behavior in our participants. Multivariate logistic regression analysis showed a significant correlation between vaccination and female sex [OR = 1.55 (95% CI = 1.25–1.92), p < 0.001], higher education level [OR = 1.49 (95% CI = 1.15–1.92), p = 0.002] patients’ knowledge [OR = 1.93 (95% CI = 1.56–2.40), p < 0.001], and their physician’s recommendation [OR = 5.12 (95% CI = 1.92–13.68), p = 0.001]. Conclusion: To increase adult immunization rates, especially among those with or at risk of cardiovascular disease (CVD), it is essential to understand each of these factors. Even if during COVID-19 pandemic, there is an increased awareness about vaccination, the vaccine acceptance level is not enough, still. Further studies and interventions are needed to improve public vaccination rates.

Background Dual antiplatelet therapy (DAPT) is the treatment of choice for patients with acute and chronic coronary syndromes as it reduces mortality and prevents recurrent thrombotic complications. The assessment of both ischaemic burden and bleeding risk is crucial in deciding which DAPT to choose and how long it should be continued. Objectives The aim of our study was to perform prospective clinical follow-up of patients receiving fixed-dose combination therapy (ASA 75 mg + clopidogrel 75 mg). Our study is a multicentric, cross-sectional, observational, cohort study. Methods A total of 1500 patients who were started on fixed-dose combination DAPT for acute or chronic coronary syndrome were included in the study. Primary endpoints were hospitalization for any reason, hospitalization for cardiovascular cause, acute myocardial infarction, stent thrombosis, target vessel revascularization and bleeding; the secondary endpoints were death for any reason or cardiovascular cause and stroke. The significance level adopted in the statistical analysis was 5%. Results Median age was 63 years; 78.5% of the patients were receiving DAPT treatment for acute coronary syndrome. The rates of hospitalization for cardiovascular reasons, acute myocardial infartion, stent thrombosis and target-vessel revascularization were 7.9%, 2.3%, 1.3% and 4.2%, respectively. While the rate of BARC type 1 bleeding was 3.3%, the rate of BARC type 5, 3, or 2 bleeding was 0.6%. The secondary endpoints which were death from any cause, cardiovascular death and stroke were 0.5%, 0.3% and 0.3%, respectively. Conclusion: Our study shows that fixed-dose combination therapy is effective and safe in appropriately selected patients with acute or chronic coronary syndromes.

This study aims to investigate the relationship between different phases of bipolar disorder (depressive, manic, and euthymic) and myocardial deformation, assessed by echocardiography, compared to healthy controls. It seeks to elucidate whether these phases of bipolar disorder are associated with different myocardial strain patterns, thus contributing to the understanding of cardiovascular implications in bipolar disorder. A cross-sectional design was employed at Dursun Odabaş Medical Centre, Psychiatry Clinic of Van Yüzüncü Yl University. The study enrolled 200 participants, divided into 4 groups: 50 in a depressive phase, 50 in a manic phase, 50 in an euthymic phase of bipolar disorder, and 50 healthy volunteers. Participants underwent detailed electrocardiographic and ECG evaluations, focusing on myocardial strain patterns and cardiac function. Statistical analyses, including ANOVA and chi-square tests, were used to compare the groups. Significant differences in global longitudinal strain (GLS) values were observed between the groups. The manic phase group exhibited the highest GLS (21.51), followed by the euthymic (20.75), depressive (20.25), and healthy control groups (19.0). The E/A ratio of the mitral valve also varied, with the manic group displaying the highest ratio (1.21). Other echocardiographic parameters such as left atria size and Ejection Fraction also differed significantly between the groups. The study concluded that the phases of bipolar disorder are associated with distinct myocardial strain patterns, as evidenced by the variation in GLS values. The findings underscore the importance of cardiac monitoring in bipolar disorder, suggesting potential cardiac risks, particularly during the manic phase. This study advocates integrated care approaches, combining psychiatric and cardiac evaluations for patients with bipolar disorder.

Background: This study examined whether the severity of mitral valve stenosis (MVS) is associated with oxidative stress (OS) markers in the blood, and other hematological and clinicodemographic parameters.Methods and Results: This prospective study was conducted between March and May 2022. Seventy-five patients with newly diagnosed MVS (25 mild, 25 moderate, 25 severe) were included. Mild, moderate, and severe MVS was defined as MV area >2, 1.5–2, and 315.5 ng/mL) and glutathione (cut-off >4.7 μmol/L).Conclusions: MVS severity seems to be affected by oxidant markers (malondialdehyde and AOPP), antioxidant enzymes (SOD), and inflammation-related cells (WBC and platelets). Future studies are needed to examine these relationships in larger populations.

Kardiyak Pace Tipi ve Pacing Modları Gamze Yeter ARSLAN Kalıcı Kalp Pili Endikasyonları Yusuf HOŞOĞLU Ayşe HOŞOĞLU Pacemaker & ICD İmplantasyonu Yakup YİĞİT Leadless Pacemaker Yusuf Ziya ŞENER Geçici Transvenöz Pacing ve Komplikasyonları Didar Elif AKGUN Yavuz Selim AKGUN Primer Koruma Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör Tarık YILDIRIM Sekonder Profilaksi Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör Seda Elçim YILDIRIM İmplante Edilebilir Kardiyoverter-Defibrilatör Programlama Arzu YAZAR İmplante Edilebilir Kardiyoverter Defibrilatör (ICD) Mevcut Hastalarda Uygun Cihaz Şoklarının Yönetimi Neşri DANIŞMAN Şeyhmus KULAHCIOĞLU Uygunsuz İmplante Edilebilir Kardiyoverter Defibrilatör (ICD) Şokları ve Yönetimi Onur ALTINKAYA Subkutan ICD Ertan AYDIN Giyilebilir Kardiyak Defibrilatör Abdullah SARIHAN Lütfü BEKAR Genetik Testler Selahattin AKYOL Holter Ritim Monitörizasyonu Sinem ÖZBAY ÖZYILMAZ İmplante Edilebilir Loop Recorder Hatice TAŞKAN Tilt Table Testi Güney SARIOĞLU Pacemaker ve ICD Endikasyonu Belirlemede Kullanılan Testler-Kardiyak Görüntüleme (EKO ve MRG) Emirhan ÇAKIR Elektrofizyolojik Çalışma Muhammed Kemal KAHYALAR Kalp Yetersizliği Tedavisinde Kardiyak Resenkronizasyon Tedavisi Enfal ÇAKMAK AKSU Fatih AKKAYA Kardiyak Resenkronizasyon Tedavisi Endikasyonları ve Hasta Seçimi Tayfur ERDOĞDU Koroner Sinüs Anatomisi ve KRT Doğan İLİŞ KRT İmplantasyonu Kubilay ERSELCAN Cerrahi KRT İmplantasyonu Mahmut YARGI Kime KRT-D & Kime KRT-P Fahri CAKAN Kardiyak Resenkronizasyon Tedavisi Yanıt Tanımı ve İlişkili Faktörler Lütfü AŞKIN Elektrokardiyografi ve Ekokardiyografi ile Kardiyak Resenkronizasyon Tedavisi Optimizasyonu Şerif HAMİDEYİN Kardiyak Resenkronizasyon Tedavisi Programlama Fatih KÖKSAL Diyafragma Pacingi Yönetimi Emre ASİLTÜRK Atriyal Fibrilasyonda Atrioventriküler (AV) Nod Ablasyonu ve Kardiyak Resenkronizasyon Tedavisi Halil İbrahim DURMUŞ HİS-Demeti Pacing Ayça ARSLAN Sol Dal Pacing İnanç ARTAÇ HİS Optimize Kardiyak Resenkranizasyon Tedavisi Süleyman BARUTCU Sol Dal Optimize Kardiyak Resenkronizasyon Tedavisi Hakan Gökalp UZUN Jeneratör Replasmanı Yusuf Bozkurt ŞAHİN Lead Ekstraksiyonu Nihan BAHADIR Kardiyak İmplante Edilebilir Elektronik Cihazların (KİEC) İmplantasyonu Sonrası Takip Şeyhmus Erkan DEMİRCAN Baver EKİNCİ Atrial Yüksek Hız Epizot Yönetimi Muhammet GENEŞ Kardiyak İmplante Edilebilir Cihazlarda Telekardiyografik Değerlendirme Zelal TAHAOĞLU Pil Cebi Hematomu Sidar Şiyar AYDIN Pnömotoraks, Hemotoraks ve Brakiyal Pleksus Yaralanması Ali Nail KAYA Kardiyak İmplante Edilebilir Elektronik Cihazların Komplikasyonu Kardiyak Rüptür/Perikardiyal Efüzyon Burcu KODAL Lead Kusurları Mert Pehlivan ALTIN Lead Dislokasyonu Sendromları Vedat CİCEK Samet YAVUZ Lead İlişkili Triküspit Yetmezliği Timor OMAR Pacemaker Aracılı Taşikardi Lütfullah CANDAN Pacemaker Sendromu Murat KARACAM Gülümser Sevgin HALİL Oversense Sendromları Selahattin AYDIN Kardiyak İmplante Edilebilir Cihaz Enfeksiyonu Mürsel ŞAHİN Kiec İlişkili Lead Trombüsü ve Pulmoner Embolizm Emre YILMAZ Karotid Baroreseptör Stimülasyonu Fehmi ESER Ramazan DUZ Kardiyak Kontraktilite Modülasyonu Sümeyye Fatma ÖZER Pulmoner Arter Basıncı Monitorizasyonu Muammer KARAKAYALI Kardiyak İmplante Edilebilir Elektronik Cihaz İmplantasyon Sürecinde Antikoagülan Tedavi ve Antibiyotik Proflaksisi Ömer ŞİT Preoperatif Kardiyak İmplante Edilebilen Cihaz Ayarlama Ferit BÖYÜK Radyoterapi Sürecinde Kalp Pili & ICD Takibi Yusuf Ziya ŞENER Kardiyak İmplante Edilebilir Elektronik Cihazı Olan Hastada Manyetik Rezonans Görüntüleme Semih KALKAN Kalp Pili & İmplante Edilebilir Kardiyak Defibrilatör (ICD) Olan Hastalarda Spor Aktivitesi ve Sürücülük Ahmet Lütfü SERTDEMİR Ahmet Taha ŞAHİN LVAD İmplantasyonu Yapılan Hastada ICD Endikasyonu ve Yönetimi Berhan KESKİN Kardiyak Cerrahi Sonrası Pacing Muhammed Bahadır OMAR TAVİ Sonrası Pacemaker İmplantasyonu Mehmet KIŞ Çisem OKTAY Konjenital Kalp Hastalıklarında Kardiyak Pacing ve ICD Mücahit TAN Naci BABAT Sarkoidoz Kardiyak Pacing ve ICD Ercan CEĞİLLİ Pakize SUCU Kardiyak Amiloidozda Kardiyak Pacing ve ICD Onur ASLAN Hipertrofik Kardiyomiyopatide Kardiyak Pacing ve ICD Burcu OZYAZGAN Nadir Kardiyak Hastalıklarda Kardiyak Pacing ve ICD Songül USALP